{"DataElement":{"publicId":"3235533","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine Analysis Serotype Defense Level Count","preferredDefinition":"The numeric value related to number of serotypes producing a defense level following the pneumococcal polyvalent vaccine.","longName":"3235523v1.0:3235529v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3235523","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine Analysis","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years._Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.","longName":"3235521v1.0:2261838v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3235521","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","longName":"C1643","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1AC3-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2261838","version":"1","preferredName":"Analysis","preferredDefinition":"Analysis; examination and interpretation.","longName":"C25391","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Analysis","conceptCode":"C25391","definition":"Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBB87D79-96F9-0549-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1AD1-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"KUMMEROA","dateModified":"2021-03-30","changeDescription":". 2021-3-30 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3235529","version":"1","preferredName":"Serotype Defense Level Count","preferredDefinition":"A characterization of a cell or microorganism based on the antigenic properties of the molecules on its surface._Protection from harm._A position on a scale measuring intensity, quality, or amount._To determine the number or amount of something; the result of this activity.","longName":"3235529v1.0","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3235528","version":"1","preferredName":"Serotype Defense Level Count","preferredDefinition":"A characterization of a cell or microorganism based on the antigenic properties of the molecules on its surface.:Protection from harm.:A position on a scale measuring intensity, quality, or amount.  (NCI):To determine the number or amount of something; the result of this activity.","longName":"C88894:C61556:C25554:C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serotype","conceptCode":"C88894","definition":"A characterization of a cell or microorganism based on the antigenic properties of the molecules on its surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Defense","conceptCode":"C61556","definition":"Protection from harm.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Level","conceptCode":"C25554","definition":"A position on a scale measuring intensity, quality, or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1B6D-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1B7E-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"KUMMEROA","dateModified":"2021-03-30","changeDescription":". 2021-3-30 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"3234637","version":"1","longName":"2131r2: Immune Deficiencies Post-HSCT Data","context":"NHLBI"},{"publicId":"3638517","version":"1","longName":"2031r2: Immune Deficiencies Pre-HSCT Data","context":"NHLBI"}]}],"AlternateNames":[{"name":"id_diag_abody_pneumoc_num","type":"NMDP_FN","context":"NHLBI"},{"name":"id_post_uncon_pneumoc_num","type":"NMDP_FN","context":"NHLBI"},{"name":"id_post_conju_pneumoc_num","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the number of serotyp","type":"Preferred Question Text","description":"What is the number of serotypes producing a protective level?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32C8E49-98AD-F201-E040-BB89AD434459","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"KUMMEROA","dateModified":"2021-03-30","changeDescription":". 2021-3-30 ak OK to release per WZ. 2021-3-4 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}